Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
James M. Wilson
University of Pennsylvania, Department: Pathology
Should you be removed from our database? Contact us at [email protected]. Read more below.
REGENXBIO, Inc.
Payment for services (e.g., consulting fees, honoraria, paid authorship)
NA
AAV Gene Therapy for Lipid Disorders
PROJECT NARRATIVE Overall The goal of this P01 is to demonstrate safety and metabolic correction of liver-directed gene therapy in patients with a severe inherited dyslipidemia that causes premature cardiovascular disease. This human proof-of- concept study can be applied across a broad array of other human metabolic diseases of relevance to heart, lung and blood diseases.
Filed on October 05, 2015.
Tell us what you know about James M. Wilson's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
James M. Wilson filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| James Wilson | University of Pennsylvania | Conflict of Interest | ReGenX Companies | $80,000 - $99,999 |
| James Wilson | University of Pennsylvania | Conflict of Interest | ReGenXBio. Inc. | $40,000 - $59,999 |
| James Wilson | University of Pennsylvania | Conflict of Interest | ReGenX Companies | Value cannot be readily determined |
| James M. Wilson | University of Pennsylvania | Conflict of Interest | REGENXBIO, Inc. | Value cannot be readily determined |
| James Wilson | University of Pennsylvania | Conflict of Interest | Dimension Therapeutics, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.